Kopran Ltd

Stage 2 · Advancing · week 24Setup 8.2 ★★★ PrimeEven −0.1

As of 20 Nov 2026, Kopran is in Stage 2, the uptrend phase, now in week 24 (since 1 Jun 2026). It closed at ₹263, 9.5% below its 52-week high and above its 200-day average, which is rising. In Health Care, 34.7% of stocks are in Stage 2.

Kopran Limited, an integrated pharmaceutical company, engages in the development, manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. More about the company

₹263.2
Close, 20 Nov 2026
-1.46% on the day
₹1,272 Cr · Small cap
Market DowntrendHealth Care 34.7% in Stage 2-11.4 pts / 20dPharmaceuticals 42.4%-13.9 pts

Pro read

Pro

Our read

Uptrend, resting below its 50-day

Setup score

8.2 ★★★ Prime

RS rank

Edge

Even −0.1

KOPRAN is about 6 months into its Stage 2 advance, 0% below its 50-day average and 10% under its 52-week high. A pause below the 50-day inside an uptrend is the weakest spot of the move until it closes back above the line.

Its relative strength is 94 of 99, a leader among NSE stocks over the past year. Pharmaceuticals ranks 7 of 106 industries by the strength of its stocks, among the leaders.

Stocks with a similar setup ran 0.1 points behind the average stock over the next 30 sessions on average, after costs, and their typical best close within 60 sessions was 17% above entry.

The trend read holds while it stays in Stage 2. A close below ₹264, its 50-day average, would put it at rest; ₹233, 20% under its 52-week high of ₹291, is where a trailing stop would sit.

Setup-score rank among Stage 2 peers: #20 of 50 in Pharmaceuticals · #27 of 61 in Health Care

Is KOPRAN early, or has it already run? Pro answers that for every NSE stock, after every close.

Loading price chart…
Stage Cycle Timeline2023-08-24 → 2026-11-20
S2 30w
S3 14w
S4 20w
S4 14w
S4 22w
S2 25w
2023-08-242026-11-20
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 30w → S3 14w → S4 5w → S1 2w → S2 13w → S3 4w → S4 20w → S1 10w → S4 14w → S1 5w → S4 22w → S1 5w → S2 25w current
Total tracked: 169 weeks across 13 stage runs.

KOPRAN among Pharmaceuticals18th of 118 by relative strength

All 118 →
Stocks in Pharmaceuticals ranked by relative strength, with stage and one-month change
#StockStageRS1M
1BLISSGVSStage 2 · wk 4999+4.6%
2KPLStage 2 · wk 4499+20.5%
3FREDUNStage 2 · wk 3398+24.0%
4VENUSREMStage 3 · wk 1098−1.5%
5RUBICONStage 3 · wk 498+18.7%
6SAKARStage 2 · wk 5598+13.1%
7BAFNAPHStage 2 · wk 2398+1.9%
8INDSWFTLABStage 2 · wk 2398−7.4%
…18KOPRANStage 2 · wk 2494−0.3%
vs 52W High
-9.5%
₹108 lo₹290.9 hi
9.5% below 52W high, pullback range
How far this stock is from its 52-week high. A stock a little below its high with its Stage 2 structure intact is in a pullback, not a breakdown.
Stage Maturity
Week 24
1w13w26w
Week 24, proven structure
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
37.6%
200 DMA: ₹191.3 · rising
The stock is above its 200-day average, the long-term trend line. That is where a Stage 2 advance normally trades.
Rel Volume
0.15x
vs 50-day avg
Volume was well below average. In a Stage 2 advance, quiet sessions read as the stock resting, not being sold.
Trend Health
↗
Short-term trend rising gently
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-0.3%
3M
+26.8%
6M
+57.4%
YTD
+74.9%
1Y
+83.8%
Sector
Health Care
↓ Peaking
Stage 2%
34.7%
20d Δ
-11.4pp
1M return
+11.5%
3M return
+3.8%
Sector Stage-2 % · last 20 days
This stock ranks #17 of 58 Stage 2 stocks in Health Care by RS.
Industry
Pharmaceuticals
↓ Peaking
Stage 2%
42.4%
20d Δ
-13.9pp
1M return
+8.3%
3M return
+2.1%
Industry Stage-2 % · last 20 days
Ranks #14 of 48 Stage 2 stocks in this industry.

Mutual fund holdings

Held by 1 mutual funds in portfolios to October 2026: 0 active funds and 1 index funds and ETFs.

In October, no active fund changed its holding.

All 1 funds and what each did in October

Mutual funds holding KOPRAN: the ten largest and the month’s moves →

Fund details on DiscoverMF

Scan Membership
Not in any scan now.
Last appeared 12 Nov 2026
Last appeared 8 Sep 2026
Last appeared 1 Jun 2026
32 appearances in the last 60 days.
Recent Stage Timeline
2026-11-20S2
Wk 24 · Vol 0.15x
2026-11-19S2
Wk 24 · Vol 0.10x
2026-11-18S2
Wk 24 · Vol 0.12x
2026-11-17S2
Wk 24 · Vol 0.24x
2026-11-16S2
Wk 24 · Vol 0.52x
2026-11-13S2
Wk 23 · Vol 0.79x
2026-11-12S2
Wk 23 · Vol 1.57x
2026-11-11S2
Wk 23 · Vol 0.19x
2026-11-09S2
Wk 23 · Vol 0.19x
2026-11-06S2
Wk 23 · Vol 0.14x
2026-11-05S2
Wk 22 · Vol 0.40x
2026-11-04S2
Wk 22 · Vol 0.33x
Moving averages & range
50 DMA
₹263.7
200 DMA
₹191.3
52W High
₹290.9
52W Low
₹108
5D Low
₹263.2
Resistance levels (recent highs)
20d High
₹289.1
60d High
₹290.9
120d High
₹290.9
250d High
₹290.9
Next resistance
+9.8%
to 20d High
P/E (TTM)
35.5
Forward 51.0
Earnings Growth (YoY)
-9.7%
Revenue +79.2%
ROE
+7.6%
Profit margin +5.0%
Dividend Yield
1.04%
P/B 2.6

Kopran: quick answers

What stage is Kopran in?

As of 20 Nov 2026, Kopran (KOPRAN) is in Stage 2, the uptrend phase. It entered Stage 2 on 1 Jun 2026 and is in week 24. What the four stages mean

Is Kopran in an uptrend?

Yes. Kopran is in a Stage 2 uptrend. It trades 37.6% above its 200-day average, which is rising.

How far is Kopran from its 52-week high?

Kopran closed at ₹263 on 20 Nov 2026, 9.5% below its 52-week high of ₹291. Its 52-week low is ₹108.

How has Kopran performed over the past year?

As of 20 Nov 2026, Kopran is up 83.8% over the past year and up 74.9% so far in 2026.

Which sector and industry is Kopran in?

Kopran is in the Pharmaceuticals industry, part of the Health Care sector. 61 stocks in Health Care are in Stage 2, 34.7% of the sector. See the Stage 2 stocks in Pharmaceuticals

About this companyHealth Care· Pharmaceuticals

Kopran Limited, an integrated pharmaceutical company, engages in the development, manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, syrups, dry powder, suspension, and injectables, as well as branded and generic formulations. It also provides drugs in the categories of macrolide, antibacterial, anticonvulsant, anti-hypertensive, anti- helminthics, anti-acne, anti-infective, anti-thrombotic, sterile carbapenem, urological, neuromodulator, antidiabetic, pain management, neuromodular, gastroenterology, and cardiovascular. In addition, the company offers drugs for erectile dysfunction, antiallergics, respiratory, oncology, central nervous system, antiprotozoal, anthelmintics, antipeptic ulcer and gut, and others. Kopran Limited was incorporated in 1958 and is based in Mumbai, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-11-20. Past data patterns are not indicative of future results. This page is a data analytics tool only.